A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell ...

Illustration showing chimeric antigen receptor (CAR) T cells attacking kidney cancer cells. [Nemes Laszlo / Science Photo Library / Getty Images] Chimeric antigen receptor (CAR) T-cell therapy is ...

In this study, we assessed the safety, feasibility, and preliminary efficacy of huCART19-IL18 in patients with relapsed or refractory lymphoma after previous anti-CD19 CAR T-cell therapy. Using a ...

CAR-T therapy caused mild cognitive impairment in mice with cancers originating in, metastasizing to and located completely outside the brain.

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting area of development for autoimmune disease treatment. Previous reports had not mentioned any particular constellation of adverse ...

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel like they have “brain fog,” or forgetfulness and difficulty ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed ...

While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. The findings, led by researchers in the ...